Blog | HemaCare

HemaCare Bone Marrow Tissue Boosts Development of Cell Therapy for Sickle Cell Disease

Dec 12, 2018 10:10:00 AM / by Nancy Andon, MSc posted in bone marrow, bone marrow-derived stem cells, sickle cell disease


An independent study cites the use of HemaCare-sourced human bone marrow-derived CD34+ stem cells for research into a potential new therapy for sickle cell disease. [1]

Sickle cell is a serious disease that affects millions of people throughout the world. People affected by sickle cell anemia have rigid, sickle-shaped red blood cells that can’t adequately carry oxygen to the body’s tissues. As a result, sickle cell patients suffer from a variety of medical complications, which can shorten their life span. Contemporary cell therapy treatments have focused on a gene therapy approach that uses lentiviral vectors to supply CD34+ bone marrow-derived stem cells with an unimpaired version of the hemoglobin gene. While this tactic has met with some promise, finding healthy, matched bone marrow donors is difficult. Researchers at Biogen, a well-known biotech firm headquartered in Cambridge, Massachusetts, are trying to discover cell and gene therapy methods that they hope will provide an alternative solution, and thereby improve treatment success rates.

Read More

Researchers Identify a Unique Marker for Bone Marrow Stem Cells

Jun 20, 2016 1:00:54 PM / by Karina Palomares posted in Bone Marrow, bone marrow-derived stem cells, hematopoietic stem cells


Stanford University scientists have identified a single marker that is only expressed in hematopoietic stem cells of the bone marrow.

Grounded in over a half of a century of research, the study of hematopoietic stem cells (HSCs) is one of the most exciting and rapidly advancing fields in medicine today. HSCs have great potential because of two cardinal properties: multipotency, defined as the ability to differentiate into all blood cell lineages, and long-term self-renewal, defined by the inexhaustible ability to produce daughter cells functionally identical to the parent upon cell division. Thus, HSC transplants have been routinely used to treat patients with malignant and non-malignant disorders of the blood and immune system.

Read More

Microglia, a Product of Bone Marrow Stem Cells, Tie up Loose Ends of Ruptured Blood Vessels

Jun 13, 2016 1:00:50 PM / by Steffen Porwollik posted in blood vessel, Bone Marrow, bone marrow, bone marrow-derived stem cells, hemorrhagic stroke, Macrophages, research, vascular repair


Scientists discover and visualize the astonishing capability of microglia, macrophages circulating in the brain, to repair broken blood vessels. This finding may open up new avenues for treatment of hemorrhagic strokes and brain microbleeds associated with dementia and cognitive decline.

Every four minutes, a person dies from a stroke in the US. A staggering 15 million people worldwide suffer from an occurrence of this disease every year. Strokes are thus incredibly common and extremely serious. The majority of these strokes is caused by a disruption of the blood flow to the brain, and therapy approaches using pluripotent stem cells show much promise. However, about 13% of strokes are hemorrhagic in nature, where brain blood vessels rupture and blood flows freely into the brain tissue.

Read More

Therapy Using Stem Cells Reduces Deaths from End-Stage Heart Failure

May 18, 2016 1:00:52 PM / by Karina Palomares posted in Bone Marrow, bone marrow-derived stem cells, heart disease, heart failure, stem cell therapy, Stem Cell Therapy, Stem Cells


Results of a phase II clinical trial show that the outcomes of end-stage heart failure can be significantly improved using stem cells from a patient’s bone marrow.

Heart failure affects approximately 5 million people in the United States, with almost 500,000 new diagnoses each year. Despite advances in treatment to prevent or minimize cardiovascular disease, the restoration of function to a damaged heart remains a major challenge. Since the heart has limited regenerative capacity, transplants are often necessary for cases of end-stage heart failure. Stem cells have the ability to home to damaged tissue and enhance regeneration and remodeling of scar tissue. Thus, therapies using stem cells may potentially lead to more effective treatments for patients with end-stage heart disease.

Read More

Bone Marrow-derived Mesenchymal Stem Cells May Put the Brakes on ALS

May 2, 2016 1:00:07 PM / by Steffen Porwollik posted in amyotrophic lateral sclerosis, autologous stem cell therapy, Bone Marrow, bone marrow, bone marrow-derived stem cells, clinical trial, Lou Gehrig's disease, neurotrophic factor, Stem Cell Therapy


A new report shows that autologous therapy with bone marrow-derived mesenchymal stem cells secreting neurotrophic factors may slow progression of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s Disease).

Henry Louis (“Lou”) Gehrig had a stellar career as first baseman for the New York Yankees. In 17 seasons, through the 1920’s and 1930’s, he hit almost 500 home runs. He seemed indefatigable and powerful, nicknamed “The Iron Horse”. That is, until, in the second half of the 1938 season, his abilities sharply deteriorated. In June 1939, he was diagnosed with amyotrophic lateral sclerosis (ALS). Lou Gehrig died two years later.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts